{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:39:01Z","timestamp":1791279541923,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jhep.2017.09.013","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T12:15:19Z","timestamp":1506687319000},"page":"586-592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Controversies in clinical trials for alcoholic hepatitis"],"prefix":"10.1016","volume":"68","author":[{"given":"Sarah R.","family":"Lieber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Lucey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2017.09.013_b0005","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/hep.28530","article-title":"Alcoholic hepatitis: Translational approaches to develop targeted therapies","volume":"64","author":"Mandrekar","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.09.013_b0010","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jhep.2015.03.006","article-title":"Trends in the management and burden of alcoholic liver disease","volume":"62","author":"Mathurin","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.09.013_b0015","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s12072-015-9701-6","article-title":"New therapeutic targets in alcoholic hepatitis","volume":"10","author":"Arsene","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2017.09.013_b0020","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2036.2004.01881.x","article-title":"Review article: current management of alcoholic liver disease","volume":"19","author":"Tome","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.09.013_b0025","series-title":"Alcohol. Non-alcoholic Fat. Liver Dis.","first-page":"195","article-title":"Diagnostic approaches and clinical end points of treatment in alcoholic liver disease","author":"Cheong","year":"2016"},{"key":"10.1016\/j.jhep.2017.09.013_b0030","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa1105703","article-title":"Early liver transplantation for severe alcoholic hepatitis","volume":"365","author":"Mathurin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.09.013_b0035","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/ajt.13586","article-title":"Early liver transplantation for severe alcoholic hepatitis in the united states\u2013a single-center experience","volume":"16","author":"Im","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2017.09.013_b0040","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.09.013_b0045","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/0003-4819-74-3-311","article-title":"Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy","volume":"74","author":"Helman","year":"1971","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2017.09.013_b0050","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1053\/j.gastro.2011.09.002","article-title":"Alcoholic liver disease: pathogenesis and new therapeutic targets","volume":"141","author":"Gao","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.09.013_b0055","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1053\/j.gastro.2015.06.006","article-title":"Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis","volume":"149","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.09.013_b0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","article-title":"Corticosteroid therapy of alcoholic hepatitis","volume":"75","author":"Maddrey","year":"1978","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.09.013_b0065","first-page":"307","article-title":"Practice guideline committee of the american association for the study of liver diseases, practice parameters committee of the american college of gastroenterology. Alcoholic liver disease","volume":"51","author":"O\u2019Shea","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.09.013_b0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2012.04.004","article-title":"EASL clinical practical guidelines: management of alcoholic liver disease","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.09.013_b0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/gut.2010.224097","article-title":"Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data","volume":"60","author":"Mathurin","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.09.013_b0080","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1365-2036.2008.03685.x","article-title":"Systematic review: glucocorticosteroids for alcoholic hepatitis\u2013a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials","volume":"27","author":"Rambaldi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.09.013_b0085","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1101214","article-title":"Glucocorticoids plus N-Acetylcysteine in Severe Alcoholic Hepatitis","volume":"365","author":"Nguyen-Khac","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.09.013_b0090","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1111\/j.1572-0241.2008.02104.x","article-title":"A new scoring system for prognostic stratification of patients with alcoholic hepatitis","volume":"103","author":"Dominguez","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.09.013_b0095","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/lt.20824","article-title":"A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation","volume":"12","author":"Cholongitas","year":"2006","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhep.2017.09.013_b0100","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1053\/he.2000.5852","article-title":"A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts","volume":"31","author":"Malinchoc","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.09.013_b0105","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.09.013_b0110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.gastro.2015.06.020","article-title":"MELDing the Lille score to more accurately predict mortality in alcoholic hepatitis","volume":"149","author":"Kamath","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.09.013_b0115","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1053\/j.gastro.2015.04.044","article-title":"Combining data from liver disease scoring systems better predicts outcomes of patients with alcoholic hepatitis","volume":"149","author":"Louvet","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.09.013_b0120","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/hepr.12597","article-title":"Prediction of long-term survival by using the Glasgow Prognostic Score in patients with hepatocellular carcinoma after liver transplantation","volume":"46","author":"Abe","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2017.09.013_b0125","article-title":"The Glasgow Prognostic Score and its variants predict mortality in living donor but not in deceased donor liver transplantation for hepatocellular carcinoma: A double-center validation study","author":"Kaltenborn","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2017.09.013_b0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cld.520","article-title":"Alcoholic foamy degeneration and alcoholic fatty liver with jaundice: Often overlooked causes of jaundice and hepatic decompensation that can mimic alcoholic hepatitis","volume":"6","author":"Roth","year":"2015","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2017.09.013_b0135","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S1665-2681(19)30938-X","article-title":"Hepatic hemodynamics and transient elastography in alcoholic foamy degeneration: report of 2 cases","volume":"11","author":"Ruiz","year":"2012","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2017.09.013_b0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-230X-13-55","article-title":"White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers","volume":"13","author":"Hardy","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2017.09.013_b0145","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1053\/j.gastro.2014.01.018","article-title":"A histologic scoring system for prognosis of patients with alcoholic hepatitis","volume":"146","author":"Altamirano","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.09.013_b0150","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jhep.2011.02.021","article-title":"The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis","volume":"55","author":"Mookerjee","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.09.013_b0155","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","article-title":"Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia","volume":"150","author":"Crabb","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.09.013_b0160","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/cld.571","article-title":"Biomarkers for monitoring alcohol use","volume":"8","author":"Cabezas","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2017.09.013_b0165","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM198707163170304","article-title":"Equipoise and the ethics of clinical research","volume":"317","author":"Freedman","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.09.013_b0170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1162\/152651602317533523","article-title":"What makes placebo-controlled trials unethical?","volume":"2","author":"Miller","year":"2002","journal-title":"Am J Bioeth"},{"key":"10.1016\/j.jhep.2017.09.013_b0175","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/0003-4819-133-6-200009190-00014","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues","volume":"133","author":"Temple","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2017.09.013_b0180","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-133-6-200009190-00015","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases","volume":"133","author":"Ellenberg","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2017.09.013_b0185","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJM200109203451211","article-title":"The ethics of placebo-controlled trials\u2013a middle ground","volume":"345","author":"Emanuel","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.09.013_b0190","doi-asserted-by":"crossref","first-page":"474","DOI":"10.7326\/0003-4819-133-6-200009190-00017","article-title":"Are placebo-controlled clinical trials ethical or needed when alternative treatment exists?","volume":"133","author":"Simon","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2017.09.013_b0195","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/1467-8519.00332","article-title":"Update on unethical use of placebos in randomised trials","volume":"17","author":"Michels","year":"2003","journal-title":"Bioethics"},{"key":"10.1016\/j.jhep.2017.09.013_b0200","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.1997.03540350075038","article-title":"World medical association declaration of Helsinki","volume":"277","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2017.09.013_b0205","unstructured":"WMA declaration of Helsinki \u2013 Ethical principles for medical research involving human subjects, 2013."},{"key":"10.1016\/j.jhep.2017.09.013_b0210","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/bmj.i124","article-title":"Decompensated alcohol related liver disease: acute management","author":"McPherson","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2017.09.013_b0215","unstructured":"Thursz M, Louvet A, Kim D, Labreuche J, Atkinson S, Sidhu S, et al. Corticosteroids are the only remaining pharmacological option for severe alcoholic hepatitis: a meta-analysis of individual data on 1974 patients. 67th Annu. Meet. Am. Assoc. Study Liver Dis., WILEY-BLACKWELL; 2016."},{"key":"10.1016\/j.jhep.2017.09.013_b0220","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1056\/NEJM199408113310611","article-title":"The continuing unethical use of placebo controls","volume":"331","author":"Rothman","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.09.013_b0225","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/ajg.2011.141","article-title":"The amount of alcohol consumption negatively impacts short-term mortality in Mexican patients with alcoholic hepatitis","volume":"106","author":"Altamirano","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.09.013_b0230","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jsat.2005.08.001","article-title":"Informed consent to undergo treatment for substance abuse: a recommended approach","volume":"29","author":"Walker","year":"2005","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.jhep.2017.09.013_b0235","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugalcdep.2006.06.011","article-title":"The need for evidence-based research ethics: a review of the substance abuse literature","volume":"86","author":"Anderson","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jhep.2017.09.013_b0240","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM197106172842404","article-title":"Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial","volume":"284","author":"Porter","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.09.013_b0245","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/0003-4819-79-5-625","article-title":"Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial","volume":"79","author":"Campra","year":"1973","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2017.09.013_b0250","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/BF01072499","article-title":"Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study","volume":"22","author":"Blitzer","year":"1977","journal-title":"Am J Dig Dis"},{"key":"10.1016\/j.jhep.2017.09.013_b0255","first-page":"443","article-title":"A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients","volume":"69","author":"Shumaker","year":"1978","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.09.013_b0260","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/0016-5085(80)90867-7","article-title":"Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy","volume":"78","author":"Depew","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.09.013_b0265","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/gut.23.1.75","article-title":"Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis","volume":"23","author":"Theodossi","year":"1982","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.09.013_b0270","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM198412063112302","article-title":"Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone","volume":"311","author":"Mendenhall","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.09.013_b0275","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/0003-4819-110-9-685","article-title":"Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial","volume":"110","author":"Carithers","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2017.09.013_b0280","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJM199202203260802","article-title":"A randomized trial of prednisolone in patients with severe alcoholic hepatitis","volume":"326","author":"Ramond","year":"1992","journal-title":"N Engl J Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817323255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817323255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T02:58:38Z","timestamp":1570157918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827817323255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0168827817323255"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2017.09.013","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in clinical trials for alcoholic hepatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2017.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}